| Oxyg vs Jin | 41–65 | 38.68% |
| Oxyg vs King | 43–61 | 41.35% |
| Oxyg vs Kazuya | 32–66 | 32.65% |
| Oxyg vs Bryan | 36–47–1 | 43.37% |
| Oxyg vs Steve | 33–37 | 47.14% |
| Oxyg vs Heihachi | 34–36 | 48.57% |
| Oxyg vs Law | 31–37 | 45.59% |
| Oxyg vs Yoshimitsu | 28–31 | 47.46% |
| Oxyg vs Paul | 26–29 | 47.27% |
| Oxyg vs Armor King | 31–23 | 57.41% |
| Oxyg vs Jun | 19–30 | 38.78% |
| Oxyg vs Dragunov | 24–23 | 51.06% |
| Oxyg vs Reina | 26–19 | 57.78% |
| Oxyg vs Asuka | 21–22 | 48.84% |
| Oxyg vs Hwoarang | 15–26 | 36.59% |
| Oxyg vs Devil Jin | 13–26 | 33.33% |
| Oxyg vs Eddy | 25–14 | 64.10% |
| Oxyg vs Anna | 14–23 | 37.84% |
| Oxyg vs Lili | 14–22 | 38.89% |
| Oxyg vs Victor | 14–18 | 43.75% |
| Oxyg vs Lee | 12–17 | 41.38% |
| Oxyg vs Azucena | 11–17 | 39.29% |
| Oxyg vs Lars | 12–15 | 44.44% |
| Oxyg vs Nina | 8–19 | 29.63% |
| Oxyg vs Xiaoyu | 10–15 | 40.00% |
| Oxyg vs Leroy | 7–18 | 28.00% |
| Oxyg vs Clive | 13–12 | 52.00% |
| Oxyg vs Claudio | 12–10 | 54.55% |
| Oxyg vs Feng | 4–17 | 19.05% |
| Oxyg vs Alisa | 12–8 | 60.00% |
| Oxyg vs Fahkumram | 6–13 | 31.58% |
| Oxyg vs Zafina | 13–5 | 72.22% |
| Oxyg vs Jack-8 | 8–5 | 61.54% |
| Oxyg vs Lidia | 6–7 | 46.15% |
| Oxyg vs Miary Zo | 6–7 | 46.15% |
| Oxyg vs Kuma | 3–6 | 33.33% |
| Oxyg vs Raven | 5–3 | 62.50% |
| Oxyg vs Leo | 4–2 | 66.67% |
| Oxyg vs Shaheen | 3–2 | 60.00% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.